The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease
Abstract
ABSTRACT &bgr;‐site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key enzyme to cleave the amyloid precursor protein to develop Alzheimer's disease (AD). Reducing BACE1 expression in central neuron through RNA interference technology shows great promise to overcome AD. However, to obtain an efficient and neurons‐specific delivery of siRNA against BACE1 through systemic administration remains challenging. Here, we design and prepare siRNA nano‐carriers based on PEGylated poly(2‐(N,N‐dimethylamino) ethyl methacrylate) (PEG‐PDMAEMA) modified with both the CGN peptide for blood‐brain barrier (BBB) penetration and the Tet1 peptide for neuron‐specific binding. The nanocomplexes CT/siRNA, composed of CGN‐PEG‐PDMAEMA and Tet1‐PEG‐PDMAEMA at a weight ratio of 1:1, display a good stability in the blood and do not lead to hemolysis at N/P=10. The internalization of nanocomplexes in neuron cells relies on clathrin‐mediated endocytosis and micropinocytosis, while caveolae‐mediated endocytosis plays a major role in entrance of CT/siRNA into cerebral capillary endothelial cell bEnd.3. The nanocomplexes successfully escape from lysosomes and enter in the cytoplasm of the neuron cells, inducing effective gene silence (about 50% decrease in BACE1 mRNA levels) and reversing A&bgr;25–35 oligomer‐induced synaptic injury. After caudal vein injection in mice, CT/siRNA display higher brain accumulation than unmodified nanocomplexes (brain drug targeting index=2.62), and colocalize with neurons or locate nearby. In APP/PS1 transgenic mice, the nanocomplexes significantly decrease BACE1 mRNA and the amyloid plaques, suppress phosphorylated tau protein levels, as well as promote hippocampal neurogenesis. Noticeably, administration of the nanocomplexes restores the cognitive performance of the AD transgenic mice to the level of wild‐type control without significant adverse effects on myelination. Our results demonstrate the CT/siRNA nanocomplexes capable of specifically directing BACE1 siRNA to brain neurons with great potential for AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Alafuzoff, I., Arzberger, T., Al‐Sarraj, S., Bodi, I., Bogdanovic, N., Braak, H., Bugiani, O., Del‐Tredici, K., Ferrer, I., Gelpi, E., et al. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00147.x · Cited by 467
Wu, H.-Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z., Spires-Jones, T., Xie, H., Arbel-Ornath, M., Grosskreutz, C. L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4456-09.2010 · Cited by 367
Desai, M. K., Sudol, K. L., Janelsins, M. C., Mastrangelo, M. A., Frazer, M. E., & Bowers, W. J. (2009) · Glia · doi:10.1002/glia.20734 · Cited by 266
Moore, N. M., Sheppard, C. L., Barbour, T. R., & Sakiyama‐Elbert, S. E. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1234 · Cited by 63
Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System
Shyam, R., Ren, Y., Lee, J., Braunstein, K. E., Mao, H.-Q., & Wong, P. C. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.15 · Cited by 58
Cited by
Drug delivery to the central nervous system
Nance, E., Pun, S. H., Saigal, R., & Sellers, D. L. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00394-w · Cited by 414
Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 300
Self-citationHan, E. L., Padilla, M. S., Palanki, R., Kim, D., Mrksich, K., Li, J. J., Tang, S., Yoon, I.-C., & Mitchell, M. J. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03509 · Cited by 72
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
“73 In targeting inflammation and oxidative stress, natural polyphenolic compounds such as quercetin, ginkgolide, and rapamycin have garnered significant attention due to their multifunctional properties, including ROS scavenging, inhibition of microglial activation, and regulation of mTOR/NF-κB…”
Li, J., Peng, H., Zhang, W., Li, M., Wang, N., Peng, C., Zhang, X., & Li, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c08756 · Cited by 43
Metadata
- Authors
- Wang, P., Zheng, X., Guo, Q., Yang, P., Pang, X., Qian, K., Lu, W., Zhang, Q., & Jiang, X.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 279
- Pages
- 220-233
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2801318634
- Cited by
- 158
- References
- 6
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jconrel.2018.04.034
- The paper
- Wang, P., Zheng, X., Guo, Q., Yang, P., Pang, X., Qian, K., Lu, W., Zhang, Q., & Jiang, X. (2018). Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2018.04.034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.